CervoMed Updates Investor Presentation and Clinical Development Disclosures

On June 15, 2026, CervoMed Inc. (NASDAQ: CRVO) filed a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure). The company announced that it has updated its corporate presentation, which contains information regarding its business operations, clinical studies, development plans, and financial position. This presentation has been made available on the company\'s official website under the "Investors – Events and Presentations" section. CervoMed indicated that its representatives may use this presentation, in whole or in part, during upcoming conferences, meetings, and discussions with investors and analysts. The information provided in the filing is considered summary information and is being furnished rather than filed, meaning it is not subject to the liabilities of Section 18 of the Exchange Act. No specific clinical trial data, regulatory milestones, or financial results were disclosed in the text of this specific filing.